H.R. 6130: Alzheimer’s Screening and Prevention Act of 2025
This bill, known as the Alzheimer’s Screening and Prevention Act of 2025 (or ASAP Act), proposes changes to Medicare that would expand coverage for early detection tests related to Alzheimer's disease and other dementias. The purpose of the bill is to facilitate the detection of Alzheimer's and related conditions at earlier stages, potentially improving treatment and care options.
Key Provisions of the Bill
1. Medicare Coverage Expansion
The bill seeks to amend the Social Security Act to include coverage for specific early detection screening tests for Alzheimer's disease and related dementias. This includes:
- Tests that are performed on or after January 1, 2028.
- Screening tests that are cleared, classified, or approved under the Federal Food, Drug, and Cosmetic Act.
- Blood-based tests that can identify pre-symptomatic and early-stage Alzheimer's disease.
2. Definition of Early Detection Tests
The bill clearly defines what constitutes an "Alzheimer’s disease and related dementias early detection screening test." Such tests include:
- Genomic sequencing blood or blood product tests.
- Other equivalent tests such as:
- Single-analyte tests
- Blood tests analyzing cell-free nucleic acids
- Multiplex panel tests
- Whole genome sequencing
- Protein expression tests
- Whole exome and whole transcriptome tests
- Medical imaging based on various biospecimens, including blood and urine.
3. Payment Adjustments
The bill calls for adjustments to the payment provisions related to Medicare coverage. It specifies that the costs for these early detection screening tests will be included under Medicare, ensuring providers are compensated for administering such tests.
Implementation Timeline
The expanded coverage for these screening tests would not take effect until the specified date of January 1, 2028, providing time for the necessary regulatory and administrative changes to be made.
Relevant Companies
- AGEF - Companies engaged in developing blood tests or diagnostic tools for Alzheimer’s and other dementias may see an increase in demand for their products as a result of this bill.
- ABT - Abbott Laboratories produces diagnostic tests and could be significantly involved in developing or providing blood-based Alzheimer’s screening tests.
- SNY - Sanofi has initiatives in CNS-related therapies and diagnostics, which could benefit from the increased focus on early detection of Alzheimer’s disease facilitated by this legislation.
This is an AI-generated summary of the bill text. There may be mistakes.
Sponsors
93 bill sponsors
-
TrackVern Buchanan
Sponsor
-
TrackAlma S. Adams
Co-Sponsor
-
TrackJake Auchincloss
Co-Sponsor
-
TrackBecca Balint
Co-Sponsor
-
TrackNanette Diaz Barragán
Co-Sponsor
-
TrackGus M. Bilirakis
Co-Sponsor
-
TrackNikki Budzinski
Co-Sponsor
-
TrackAndré Carson
Co-Sponsor
-
TrackEd Case
Co-Sponsor
-
TrackJuan Ciscomani
Co-Sponsor
-
TrackGilbert Ray Cisneros, Jr.
Co-Sponsor
-
TrackTom Cole
Co-Sponsor
-
TrackAngie Craig
Co-Sponsor
-
TrackJason Crow
Co-Sponsor
-
TrackSharice Davids
Co-Sponsor
-
TrackDebbie Dingell
Co-Sponsor
-
TrackMike Ezell
Co-Sponsor
-
TrackShomari Figures
Co-Sponsor
-
TrackScott Fitzgerald
Co-Sponsor
-
TrackBrian K. Fitzpatrick
Co-Sponsor
-
TrackLois Frankel
Co-Sponsor
-
TrackJohn Garamendi
Co-Sponsor
-
TrackVicente Gonzalez
Co-Sponsor
-
TrackMaggie Goodlander
Co-Sponsor
-
TrackJosh Gottheimer
Co-Sponsor
-
TrackGlenn Grothman
Co-Sponsor
-
TrackJahana Hayes
Co-Sponsor
-
TrackJared Huffman
Co-Sponsor
-
TrackBill Huizenga
Co-Sponsor
-
TrackJonathan L. Jackson
Co-Sponsor
-
TrackPramila Jayapal
Co-Sponsor
-
TrackHenry C. "Hank" Johnson, Jr.
Co-Sponsor
-
TrackJulie Johnson
Co-Sponsor
-
TrackMike Kelly
Co-Sponsor
-
TrackTimothy M. Kennedy
Co-Sponsor
-
TrackRo Khanna
Co-Sponsor
-
TrackJennifer Kiggans
Co-Sponsor
-
TrackKevin Kiley
Co-Sponsor
-
TrackYoung Kim
Co-Sponsor
-
TrackRaja Krishnamoorthi
Co-Sponsor
-
TrackDarin LaHood
Co-Sponsor
-
TrackNick LaLota
Co-Sponsor
-
TrackGreg Landsman
Co-Sponsor
-
TrackNicholas A. Langworthy
Co-Sponsor
-
TrackRick Larsen
Co-Sponsor
-
TrackGeorge Latimer
Co-Sponsor
-
TrackMichael Lawler
Co-Sponsor
-
TrackTed Lieu
Co-Sponsor
-
TrackStephen F. Lynch
Co-Sponsor
-
TrackRyan Mackenzie
Co-Sponsor
-
TrackNicole Malliotakis
Co-Sponsor
-
TrackTracey Mann
Co-Sponsor
-
TrackSarah McBride
Co-Sponsor
-
TrackApril McClain Delaney
Co-Sponsor
-
TrackBetty McCollum
Co-Sponsor
-
TrackKristen McDonald Rivet
Co-Sponsor
-
TrackAddison McDowell
Co-Sponsor
-
TrackGrace Meng
Co-Sponsor
-
TrackCarol D. Miller
Co-Sponsor
-
TrackJoseph D. Morelle
Co-Sponsor
-
TrackKelly Morrison
Co-Sponsor
-
TrackSeth Moulton
Co-Sponsor
-
TrackKevin Mullin
Co-Sponsor
-
TrackJoe Neguse
Co-Sponsor
-
TrackDonald Norcross
Co-Sponsor
-
TrackEleanor Holmes Norton
Co-Sponsor
-
TrackIlhan Omar
Co-Sponsor
-
TrackBurgess Owens
Co-Sponsor
-
TrackBrittany Pettersen
Co-Sponsor
-
TrackAugust Pfluger
Co-Sponsor
-
TrackChellie Pingree
Co-Sponsor
-
TrackMark Pocan
Co-Sponsor
-
TrackJohn H. Rutherford
Co-Sponsor
-
TrackPatrick Ryan
Co-Sponsor
-
TrackMaria Elvira Salazar
Co-Sponsor
-
TrackChristopher H. Smith
Co-Sponsor
-
TrackLloyd Smucker
Co-Sponsor
-
TrackEric Sorensen
Co-Sponsor
-
TrackDarren Soto
Co-Sponsor
-
TrackSuhas Subramanyam
Co-Sponsor
-
TrackEmilia Strong Sykes
Co-Sponsor
-
TrackClaudia Tenney
Co-Sponsor
-
TrackMike Thompson
Co-Sponsor
-
TrackRashida Tlaib
Co-Sponsor
-
TrackPaul Tonko
Co-Sponsor
-
TrackRitchie Torres
Co-Sponsor
-
TrackLori Trahan
Co-Sponsor
-
TrackDerrick Van Orden
Co-Sponsor
-
TrackGabe Vasquez
Co-Sponsor
-
TrackEugene Vindman
Co-Sponsor
-
TrackJames R. Walkinshaw
Co-Sponsor
-
TrackJoe Wilson
Co-Sponsor
-
TrackRobert J. Wittman
Co-Sponsor
Actions
2 actions
| Date | Action |
|---|---|
| Nov. 19, 2025 | Introduced in House |
| Nov. 19, 2025 | Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. |
Corporate Lobbying
0 companies lobbying
None found.
* Note that there can be significant delays in lobbying disclosures, and our data may be incomplete.
